Merck KGaA to acquire Silence Therapeutics for about $1.3 billion on October 20, 2026 acquisition divesiran Merck KGaA Polycythemia RNA, Small Interfering Silence Therapeutics vera +
Merck KGaA to acquire Silence Therapeutics for about $1.3 billion on October 19, 2026 acquisition divesiran Merck KGaA Phase 2 Polycythemia Vera RNA, Small Interfering Silence Therapeutics +
Disc challenges in polycythemia vera, but Silence retains the lead on September 11, 2026 Disc Medicine DISC-3405 divesiran hepcidin Phase 2 trial Phase 3 development Polycythemia SANRECO Silence Therapeutics TMPRSS6 gene vera +
Phase II win for Silence's divesiran in PV lifts bar for Takeda's rusfertide on August 12, 2026 88% Clinical Response divesiran dosing Frequency of Responses Hepcidin mimetics NDA Perl50 Phase II SANRECO Polycythemia Priority Review siRNA therapy Takeda rusfertide Trimonthly Venous blood sampling vera PV +
Gene‑silencing drug divesiran posts strong Phase 2 win in rare blood cancer on August 11, 2026 divesiran gene-silencing Hematocrit procedure Hematologic Neoplasms Hepcidin Infrequent Polycythemia RNA, Small Interfering rusfertide SANRECO Silence Therapeutics ' Takeda TMPRSS6 gene Venous blood sampling Vera +